Works by Jones, Suzanne


Results: 93
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.

    Published in:
    British Journal of Cancer, 2023, v. 128, n. 10, p. 1906, doi. 10.1038/s41416-023-02185-2
    By:
    • Johnson, Melissa L.;
    • Wang, Judy S.;
    • Falchook, Gerald;
    • Greenlees, Carol;
    • Jones, Suzanne;
    • Strickland, Donald;
    • Fabbri, Giulia;
    • Kennedy, Caroline;
    • Elizabeth Pease, J.;
    • Sainsbury, Liz;
    • MacDonald, Alexander;
    • Schalkwijk, Stein;
    • Szekeres, Philip;
    • Cosaert, Jan;
    • Burris III, Howard
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31

    Detachment of Pacemaker Active Fixation Helix.

    Published in:
    Pacing & Clinical Electrophysiology, 1983, v. 6, n. 3, p. 818, doi. 10.1111/j.1540-8159.1983.tb05347.x
    By:
    • Dawkins, Keith D.;
    • Jones, Suzanne;
    • Ward, David E.
    Publication type:
    Article
    32

    A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

    Published in:
    2015
    By:
    • Bendell, Johanna C.;
    • Kelley, Robin K.;
    • Shih, Kent C.;
    • Grabowsky, Jennifer A.;
    • Bergsland, Emily;
    • Jones, Suzanne;
    • Martin, Thomas;
    • Infante, Jeffrey R.;
    • Mischel, Paul S.;
    • Matsutani, Tomoo;
    • Xu, Shuichan;
    • Wong, Lilly;
    • Liu, Yong;
    • Wu, Xiaoling;
    • Mortensen, Deborah S.;
    • Chopra, Rajesh;
    • Hege, Kristen;
    • Munster, Pamela N.
    Publication type:
    journal article
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum].

    Published in:
    International Journal of Nanomedicine, 2019, v. 14, p. 5751, doi. 10.2147/IJN.S207276
    By:
    • Wu, Huali;
    • Infante, Jeffrey R;
    • Keedy, Vicki L;
    • Jones, Suzanne F;
    • Chan, Emily;
    • Bendell, Johanna C;
    • Lee, Wooin;
    • Kirschbrown, Whitney P;
    • Zamboni, Beth A;
    • Ikeda, Satoshi;
    • Kodaira, Hiroshi;
    • Rothenberg, Mace L;
    • III, Howard A Burris;
    • Zamboni, William C
    Publication type:
    Article
    44

    Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

    Published in:
    International Journal of Nanomedicine, 2015, v. 10, p. 1201, doi. 10.2147/IJN.S62911
    By:
    • Huali Wu;
    • Infante, Jeffrey R.;
    • Keedy, Vicki L.;
    • Jones, Suzanne F.;
    • chan, Emily;
    • Bendell, Johanna C.;
    • lee, Wooin;
    • Kirschbrown, Whitney P.;
    • Zamboni, Beth A.;
    • Ikeda, Satoshi;
    • Kodaira, Hiroshi;
    • Rothenberg, Mace L.;
    • Burris III, Howard A.;
    • Zamboni, William C.
    Publication type:
    Article
    45
    46
    47

    Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.

    Published in:
    Nature Communications, 2016, v. 7, n. 8, p. 12624, doi. 10.1038/ncomms12624
    By:
    • Wallin, Jeffrey J.;
    • Bendell, Johanna C.;
    • Funke, Roel;
    • Sznol, Mario;
    • Korski, Konstanty;
    • Jones, Suzanne;
    • Hernandez, Genevive;
    • Mier, James;
    • He, Xian;
    • Hodi, F. Stephen;
    • Denker, Mitchell;
    • Leveque, Vincent;
    • Cañamero, Marta;
    • Babitski, Galina;
    • Koeppen, Hartmut;
    • Ziai, James;
    • Sharma, Neeraj;
    • Gaire, Fabien;
    • Chen, Daniel S.;
    • Waterkamp, Daniel
    Publication type:
    Article
    48
    49
    50